Global Health Investment Advisors (dba Global Health Funds) served as the Investment Manager for the pioneering Global Health Investment Fund (“GHIF”) from 2015 through the fund’s conclusion in 2023. GHIF made 12 investments, producing top quartile financial returns and introducing over a dozen new products to the market. These products, ranging from the Jada device for postpartum hemorrhage, to the Euvichol vaccine for cholera, to the AtomoRapid tests for HIV, have improved and saved millions of lives globally.

We currently advise AXA Investment Managers’ Prime Impact Fund, which expands on the work from GHIF.